Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29680516 | 0.82 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL24535699 | 0.82 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL31256358 | 0.80 | ESR1 (0.34) | ESR1ESR2 | |
| SCHEMBL31256282 | 0.73 | LPL (0.32) | — | |
| SCHEMBL31256097 | 0.70 | CYP3A4 (0.34) | ESR1 | |
| SCHEMBL15130343 | 0.69 | CYP3A4 (0.39) | ESR1ESR2 | |
| SCHEMBL12642107 | 0.69 | CA1 (0.31) | — | |
| SCHEMBL31256325 | 0.69 | F2 (0.30) | — | |
| SCHEMBL264135 | 0.68 | HSD17B10 (0.42) | ESR1ESR2 | |
| SCHEMBL10269959 | 0.68 | HSD17B10 (0.42) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2024243186-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | NRAS, KRAS, HRAS | ESR1 4251/4885ESR2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.